OpenLB
Open Library of Bioscience
Advanced Search
The Lancet. Infectious diseases
01, 2019;19 (1): 91-101.

Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.

Robert J Commons, Julie A Simpson, Kamala Thriemer, Mohammad S Hossain, Nicholas M Douglas, Georgina S Humphreys, Carol H Sibley, Philippe J Guerin, Ric N Price
Author Information
  1. Robert J Commons: Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network, Oxford, UK. Electronic address: rob.commons@wwarn.org.
  2. Julie A Simpson: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  3. Kamala Thriemer: Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.
  4. Mohammad S Hossain: Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network, Oxford, UK; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
  5. Nicholas M Douglas: Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  6. Georgina S Humphreys: WorldWide Antimalarial Resistance Network, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  7. Carol H Sibley: WorldWide Antimalarial Resistance Network, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
  8. Philippe J Guerin: WorldWide Antimalarial Resistance Network, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  9. Ric N Price: Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
PMID: 30587297 DOI: 10.1016/S1473-3099(18)30596-6

Abstract

BACKGROUND: A 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for all patients with uncomplicated malaria in co-endemic regions.
METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, Web of Science, and the Cochrane Database of Systematic Reviews for prospective clinical studies in any language, published between Jan 1, 1960, and Jan 5, 2018, assessing drug efficacy in patients with uncomplicated P falciparum malaria in countries co-endemic for P vivax. Studies were included if the presence or absence of P vivax parasitaemia was recorded after treatment. The primary outcome was the risk of P vivax parasitaemia between day 7 and day 42 after initiation of antimalarial treatment for P falciparum, with the pooled risk calculated by random-effects meta-analysis. We compared the risk of P vivax parasitaemia after treatment with different artemisinin-based combination therapies (ACTs). This study is registered with PROSPERO, number CRD42017064838.
FINDINGS: 153 of 891 screened studies were included in the analysis, including 31 262 patients from 323 site-specific treatment groups: 130 (85%) studies were from the Asia-Pacific region, 16 (10%) from the Americas, and seven (5%) from Africa. The risk of P vivax parasitaemia by day 42 was 5·6% (95% CI 4·0-7·4; I=92·0%; 117 estimates). The risk of P vivax parasitaemia was 6·5% (95% CI 4·6-8·6) in regions of short relapse periodicity compared with 1·9% (0·4-4·0) in regions of long periodicity, and was greater after treatment with a more rapidly eliminated ACT: 15·3% (5·1-29·3) for artemether-lumefantrine compared with 4·5% (1·2-9·3) for dihydroartemisinin-piperaquine and 5·2% (2·9-7·9) for artesunate-mefloquine. Recurrent parasitaemia was delayed in patients treated with ACTs containing mefloquine or piperaquine compared with artemether-lumefantrine, but by day 63 the risk of vivax parasitaemia was more than 15% for all ACTs assessed.
INTERPRETATION: Our findings show a high risk of vivax parasitaemia after treatment of falciparum malaria, particularly in areas with short relapse periodicity and after rapidly eliminated treatment. In co-endemic regions, universal radical cure for all patients with uncomplicated malaria has the potential to substantially reduce recurrent malaria.
FUNDING: Australian National Health and Medical Research Council, Royal Australasian College of Physicians, Wellcome Trust, and Bill & Melinda Gates Foundation.

References

  1. Antimicrob Agents Chemother. 2000 Mar;44(3):697-704 [PMID: 10681341]
  2. Lancet. 2007 Mar 3;369(9563):757-765 [PMID: 17336652]
  3. Malar J. 2008 Aug 02;7:149 [PMID: 18673575]
  4. N Engl J Med. 2008 Dec 11;359(24):2545-57 [PMID: 19064624]
  5. BMJ. 2009 Jul 21;339:b2700 [PMID: 19622552]
  6. Lancet Infect Dis. 2010 Jun;10(6):405-16 [PMID: 20510281]
  7. Lancet Infect Dis. 2010 Oct;10(10):673-81 [PMID: 20832366]
  8. Clin Infect Dis. 2011 Mar 1;52(5):612-20 [PMID: 21292666]
  9. Malar J. 2011 Aug 31;10:253 [PMID: 21880138]
  10. Malar J. 2011 Oct 11;10:297 [PMID: 21989376]
  11. Int J Parasitol. 2012 Nov;42(12):1049-54 [PMID: 22968164]
  12. PLoS Negl Trop Dis. 2012;6(9):e1814 [PMID: 22970336]
  13. Adv Parasitol. 2012;80:271-300 [PMID: 23199490]
  14. Lancet Infect Dis. 2013 Oct;13(10):900-6 [PMID: 23809889]
  15. PLoS Med. 2013 Dec;10(12):e1001575; discussion e1001575 [PMID: 24358031]
  16. Malar J. 2014 Apr 15;13:144 [PMID: 24731298]
  17. J Antimicrob Chemother. 2015 Mar;70(3):868-76 [PMID: 25377567]
  18. BMC Med. 2014 Nov 18;12:217 [PMID: 25406857]
  19. Int J Evid Based Healthc. 2015 Sep;13(3):147-53 [PMID: 26317388]
  20. PLoS Med. 2017 Jan 10;14(1):e1002212 [PMID: 28072872]
  21. PLoS Med. 2017 May 16;14(5):e1002299 [PMID: 28510573]
  22. Lancet. 1987 Nov 7;2(8567):1052-5 [PMID: 2889965]
  23. Clin Infect Dis. 2018 Oct 30;67(10):1543-1549 [PMID: 29889239]
  24. J Travel Med. 2018 Jan 1;25(1):null [PMID: 30137454]
  25. Lancet. 1984 Dec 15;2(8416):1360-1 [PMID: 6150365]
  26. J Infect Dis. 1994 Apr;169(4):932-5 [PMID: 8133114]
  27. BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]

Grants

  1. /Wellcome Trust
  2. 200909/Z/16/Z/Wellcome Trust

MeSH Term

Adolescent
Adult
Antimalarials
Artemisinins
Child
Child, Preschool
Coinfection
Female
Humans
Malaria, Falciparum
Malaria, Vivax
Male
Parasitemia
Plasmodium falciparum
Plasmodium vivax
Quinolines
Risk
Treatment Outcome
Young Adult

Chemicals

Antimalarials
Artemisinins
Quinolines
Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review
Article has an altmetric score of 14

Word Cloud

Created with Highcharts 10.0.0vivaxparasitaemiaPrisktreatmentmalariaPlasmodiumfalciparumpatientsregionsdaycomparedradicalcureuncomplicatedco-endemicmeta-analysisstudiesACTsperiodicityusedantimalarialpotentialsystematicreviewJanincluded4295%CIshortrelapserapidlyeliminatedartemether-lumefantrineBACKGROUND:14-daycourseprimaquineovalequantifiedcommonlydrugsassessbenefitsMETHODS:searchedMEDLINEEmbaseWebScienceCochraneDatabaseSystematicReviewsprospectiveclinicallanguagepublished1196052018assessingdrugefficacycountriesStudiespresenceabsencerecordedprimaryoutcome7initiationpooledcalculatedrandom-effectsdifferentartemisinin-basedcombinationtherapiesstudyregisteredPROSPEROnumberCRD42017064838FINDINGS:153891screenedanalysisincluding31 262323site-specificgroups:13085%Asia-Pacificregion1610%Americasseven5%Africa5·6%4·0-7·4I=92·0%117estimates6·5%4·6-8·61·9%0·4-4·0longgreaterACT:15·3%5·1-29·34·5%1·2-9·3dihydroartemisinin-piperaquine5·2%2·9-7·9artesunate-mefloquineRecurrentdelayedtreatedcontainingmefloquinepiperaquine6315%assessedINTERPRETATION:findingsshowhighparticularlyareasuniversalsubstantiallyreducerecurrentFUNDING:AustralianNationalHealthMedicalResearchCouncilRoyalAustralasianCollegePhysiciansWellcomeTrustBill&MelindaGatesFoundationRiskinfection:

Similar Articles

Cited By